Ishares Nasdaq Biotechnology Index Fund
IBBNASDAQStock · Data from SEC EDGAR 13F · Held by 3 of 87 tracked investors
Ishares Nasdaq Biotechnology Index Fund at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation55
- Growth–
- Profitability–
- Quality–
- Debt–
- Stability–
The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.
Is the stock expensive?
Reasonably pricedFor 1 USD of annual earnings you pay 26.3 USD.
- P/E
- 26.3×
- P/S
- –
- EV/EBITDA
- –
Is the company growing?
–Too few years to compare. Last year –.
Does it make money?
–Net margin: –.
Is it financially healthy?
–- Cash
- –
- Debt
- –
- Free CF
- –
Free cash flow is not enough to repay the debt.
Does it pay a dividend?
No dividendChart IBB
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
3GI Generali Investments CEE Generali Investments CEE | 1.05% |
JG Joel Greenblatt Gotham Asset Management | 0.01% |
KF Ken Fisher Fisher Investments | 0% |
Frequently asked questions
How much is Ishares Nasdaq Biotechnology Index Fund (IBB) stock?
Ishares Nasdaq Biotechnology Index Fund shares trade at $212.20, +1.68% over the last trading day. The price is delayed.
Which big investors hold Ishares Nasdaq Biotechnology Index Fund?
According to the latest 13F filings, 3 of 87 tracked investors hold Ishares Nasdaq Biotechnology Index Fund, for example Generali Investments CEE, Joel Greenblatt, Ken Fisher.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.